Literature DB >> 17805238

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.

D Russo1, I Miranda, C Ruocco, Y Battaglia, E Buonanno, S Manzi, L Russo, A Scafarto, V E Andreucci.   

Abstract

Coronary artery calcification is more prevalent in dialysis patients than in patients without kidney disease and this is associated with high serum phosphorus. In this study, we evaluate the effect of calcium carbonate or sevelamer treatments on the progression of calcification in 90 predialysis patients. Inclusion criteria were stable serum calcium, phosphorus, parathyroid hormone, and a similar baseline total calcium score (TCS). These patients were not treated by phosphate binder, vitamin D, or statin. They were given low-phosphorus diets without or with daily calcium carbonate or sevelamer throughout the study that averaged 2 years. Baseline demographic or clinical characteristics along with biochemical parameters were not different among the three groups. The TCS significantly increased in patients on the low-phosphorus diet alone, to a lesser extent in calcium carbonate-treated patients, and not at all in sevelamer-treated patients. The progression of coronary calcification paralleled that of the calcium score. Our study shows that sevelamer treatment should not be restricted to dialysis patients; however, a larger study should be undertaken to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805238     DOI: 10.1038/sj.ki.5002518

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  108 in total

1.  Approach to cardiovascular disease prevention in patients with chronic kidney disease.

Authors:  Cristina Karohl; Paolo Raggi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

Review 3.  The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals.

Authors:  Solmaz Khoshniat; Annabelle Bourgine; Marion Julien; Pierre Weiss; Jérôme Guicheux; Laurent Beck
Journal:  Cell Mol Life Sci       Date:  2010-09-17       Impact factor: 9.261

Review 4.  The role of phosphorus in the development and progression of vascular calcification.

Authors:  Jessica Kendrick; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2011-09-28       Impact factor: 8.860

5.  Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.

Authors:  Yusuke Izumi; Mutsuharu Hayashi; Ryota Morimoto; Xian Wu Cheng; Hongxian Wu; Hideki Ishii; Yoshinari Yasuda; Daiji Yoshikawa; Hideo Izawa; Seiichi Matsuo; Yutaka Oiso; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2014-08-24       Impact factor: 2.037

Review 6.  Coronary artery calcification in chronic kidney disease: An update.

Authors:  Tomasz Stompór
Journal:  World J Cardiol       Date:  2014-04-26

Review 7.  Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Authors:  Caroline M Perry; Greg L Plosker
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

8.  Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

Authors:  Mario Cozzolino; Maria Antonietta Rizzo; Andrea Stucchi; Daniele Cusi; Maurizio Gallieni
Journal:  Ther Adv Chronic Dis       Date:  2012-03       Impact factor: 5.091

Review 9.  The emerging role of phosphate in vascular calcification.

Authors:  Cecilia M Giachelli
Journal:  Kidney Int       Date:  2009-01-14       Impact factor: 10.612

Review 10.  Clinical features of CKD-MBD in Japan: cohort studies and registry.

Authors:  Takayuki Hamano; Yusuke Sakaguchi; Naohiko Fujii; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2016-12-09       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.